ORCHPHARMA2024-10-012024-12-31 ORCHPHARMA2024-10-012024-12-31 ORCHPHARMA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member ORCHPHARMA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member ORCHPHARMA2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524372 ORCHPHARMA NOTLISTED Orchid Pharma Limited Equity 2024-04-01 2025-03-31 2025-02-12 2025-02-06 INR Lakhs Third quarter 12:10:00 15:20:00 2025-02-12 2025-02-12 Not applicable Single segment Pharmaceuticals 2024-10-01 2024-12-31 Unaudited Consolidated 2173425000.00 84900000.00 2258325000.00 1420213000.00 13691000.00 -185988000.00 220584000.00 37975000.00 86050000.00 441300000.00 2033825000.00 224500000.00 0.00 224500000.00 0.00 0.00 0.00 0.00 224500000.00 0.00 0.00 0.00 -16749000.00 207751000.00 -8014000.00 199737000.00 0.00 0.00 0.00 0.00 507191000.00 10 4.10 4.10 0.00 0.00 4.10 4.10 1. The above results for the quarter and nine months ended Decemeber 31, 2024 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on February 12, 2025.The statutory auditors of the company have expressed a modified conclusion on the Limited review. 2. The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards (“Ind AS”) as prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. 3. 99,02,705 fully paid up Equity shares of Rs.10/- each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement (QIP) whereby proceeds of Rs.39180 Lakhs (Net of Share issue expenses) was raised. As on December 31, 2024 the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below : Statement of QIP Net Funds raised and utilisation Particulars Amount as stated in Total amount utilised *Balance amount as on Remarks the Offer Document upto December 31, 2024 on December 31, 2024 kept (Rs. In Lakhs) (Rs. In Lakhs) in Fixed Deposits (in lakhs) 1)Investment in OBPL (subsidiary) for setting up Jammu Manufacturing Facility 9000 2120 6880 2)Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the company 14100 14100 - 3)Funding capital expenditure requirements for setting up a new block at the API facility of the Company in Alathur, Tamil Nadu 9982 36 9946 4)General corporate purposes 6098 3768 2604 # Total 39180 20024 19430 #As per the QIP offer Document the amount allocated for General Corporate Purpose (GCP) was Rs. 6098 Lakh which was based on the proposed net proceeds after issue expenses being Rs.39180 Lakh. However, net proceeds transferred to Monitoring Account was Rs. 39454 Lakh as against the proposed net Proceeds of Rs. 39180 Lakh, therefore the Surplus amount of Rs. 274 Lakh has been included in the GCP balance as on December 31, 2024. * Balance amount excludes the interest earned on the unutilized QIP funds kept in fixed deposits. 4. The operations of the Company falls under a single operating segment i.e., Pharmaceuticals in accordance with Ind AS 108 ''Operating Segments and hence no reporting as per Ind AS 108 is applicable. 5. The Company has submitted a petition with the Hon’ble National Company Law Tribunal, Chennai bench, for amalgamation of its Holding Company Dhanuka Laboratories Limited (“the Amalgamating Company”) with the Company in compliance with Section 230-232 and other relevant provisions of the Companies Act 2013 . The scheme of amalgamation had been approved by the Board of Directors of the respective Companies. Further, in compliance with the SEBI Listing Regulations and Master Circulars issued thereon, the Company has obtained Observation Letter from the BSE Limited and National Stock Exchange of India Limited (“stock exchanges”) giving No objection to the said amalgamation. 6. Figures of the previous period have been regroupted/reclassified /restated wherever considered necessary. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 6844472000.00 235775000.00 7080247000.00 4485160000.00 13691000.00 -436787000.00 641182000.00 106251000.00 256741000.00 1249302000.00 6315540000.00 764707000.00 0.00 764707000.00 -1541000.00 0.00 -1541000.00 0.00 766248000.00 0.00 0.00 0.00 7374000.00 773622000.00 -24188000.00 749434000.00 0.00 0.00 0.00 0.00 507191000.00 10 15.25 15.25 0.00 0.00 15.25 15.25 Other Expenses 441300000.00 Other Expenses 1249302000.00 -8014000.00 -24188000.00 0.00 0.00 0.00 0.00